AtriCure, Inc. (NASDAQ:ATRC) is scheduled to release its earnings data after the market closes on Thursday, July 27th. Analysts expect AtriCure to post earnings of ($0.26) per share for the quarter.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, May 4th. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01. The business had revenue of $41.30 million for the quarter, compared to analyst estimates of $40.25 million. AtriCure had a negative net margin of 21.07% and a negative return on equity of 19.89%. AtriCure’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.31) earnings per share. On average, analysts expect AtriCure to post $-0.96 EPS for the current fiscal year and $-0.66 EPS for the next fiscal year.

AtriCure, Inc. (NASDAQ:ATRC) opened at 23.91 on Thursday. The firm’s market cap is $811.65 million. AtriCure, Inc. has a 12-month low of $13.45 and a 12-month high of $25.11. The company has a 50-day moving average of $23.06 and a 200 day moving average of $19.84.

ATRC has been the topic of a number of recent research reports. Zacks Investment Research raised shares of AtriCure from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Tuesday, May 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of AtriCure in a research note on Monday, April 17th. ValuEngine raised shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $26.00 price target on shares of AtriCure in a research note on Tuesday, May 30th. Finally, TheStreet raised shares of AtriCure from a “d+” rating to a “c-” rating in a research note on Monday, May 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $22.60.

TRADEMARK VIOLATION WARNING: “AtriCure, Inc. (NASDAQ:ATRC) Set to Announce Earnings on Thursday” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/20/atricure-inc-nasdaqatrc-set-to-announce-earnings-on-thursday.html.

In other news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $21.44, for a total value of $214,400.00. Following the sale, the director now owns 24,162 shares of the company’s stock, valued at $518,033.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 10.00% of the company’s stock.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Earnings History for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.